The problem

Heart disease is the leading cause of death in the United States and the second in Canada. Heart failure alone accounts for over 1.2 million U.S. hospital admissions a year, and inpatient care is the largest share of a cost that runs to tens of billions of dollars annually. Most of those admissions are for the same thing: congestion from fluid overload.

Monitoring today

Outpatient management of heart failure and decompensated cirrhosis relies on daily weight and clinic visits that are typically weeks apart. Weight is a late and non-specific signal, and it depends on the patient stepping on a scale every day. Peripheral edema is graded by eye or with a tape measure, both of which are subjective and poorly reproducible. None of these methods is suited to detecting the gradual fluid shifts that precede a decompensation.

Peripheral fluid, by contrast, accumulates where it can be measured directly: at the ankle.

Who is affected

Derivation and references are in our market analysis memorandum, available on request. All figures are literature-based estimates with conservative extrapolation; we have not generated our own epidemiological data.

Why it matters to the system

A single heart failure or cirrhosis hospitalization commonly costs $15,000 to $20,000 in the United States, and readmission within weeks is frequent. From a payer or health-system perspective, the economic question is not whether admissions can be eliminated but whether a modest fraction can be avoided at a per-patient monitoring cost that is a small fraction of one admission. That arithmetic is what we intend to test, not assume.